EISAI ANNOUNCES NEW PARTNERSHIP WITH ESTEVE
AN ALLIANCE TO PROMOTE ANTI-EPILEPSY DRUG ZONEGRAN® (ZONISAMIDE) IN SPAIN.
Eisai announces today that it has selected Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to become its epilepsy partner in Spain to promote Zonegran® (zonisamide). Zonisamide, a novel anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AED, is indicated as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; and as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents and children aged six years and above 1.
"As a research-based pharmaceutical company with a particular focus on epilepsy, we are not only committed to bringing innovative new therapies to market, but also ensuring that we maximise access to our currently licensed products", comments Gary Hendler, President and CEO, Eisai EMEA. "Our partnership with one of Spain's leading pharmaceutical companies, Esteve for Zonegran in Spain will allow Eisai to focus our efforts and resources on a broad epilepsy portfolio, and we believe strongly that our new promotion strategy will allow us to become the leading company in epilepsy by 2015."
"The alliance in epilepsy between Esteve and Eisai is a new milestone for our company and will allow us to foster and consolidate our presence in one of our core business areas: central nervous system" explains Albert Esteve, CEO of Esteve.
Epilepsy is a common neurological condition that causes recurrent seizures in the brain. It is usually diagnosed in children and people over 65 years of age, although it can affect anyone 1. Currently, up to 22,000 people are diagnosed with epilepsy each year in Spain, of whom around one third have seizures that are not completely controlled by their anti-epileptic therapy 2.
The new partnership with Esteve in Spain is yet another example of Eisai's human health care mission. Eisai is committed to the therapeutic area of epilepsy and addressing the unmet medical needs of people with epilepsy. Eisai is proud to currently market more epilepsy products in EMEA than any other company, and is dedicated to becoming the number one epilepsy company in Europe (by sales) by 2015, as stated in its Hayabusa plan.
Epilepsy is one of the most common neurological conditions in the world 3 4, affecting approximately eight in 1,000 people in Europe, and an estimated 50 million people worldwide , Epilepsy is a chronic disorder of the brain that affects people of all ages. It is characterised by abnormal discharges of neuronal activity causing seizures. Seizures can vary in severity, from brief lapses of attention or jerking of muscles, to severe and prolonged convulsions. Depending on the seizure type, seizures may be limited to one part of the body, or may involve the whole body. Seizures can also vary in frequency from less than one per year, to several per day. Epilepsy has many possible causes but often the cause is unknown.
1 Eisai Ltd 2013. Zonegran Summary of Product Characteristics
2 Epilepsy Research UK. What is Epilepsy? Ficha técnica. Disponible en URL:
http://epilepsyresearch.org.uk/wp-content/uploads/2012/03/1_what_is_epilepsy.pdf (Visto por última vez en mayo 2013)
3 García-Ramos R, et al. Neurología. 2011; 26:54855. http://www.elsevier.es/sites/default/files/elsevier/eop/S2173-5808(11)00042-3.pdf (Visto por última vez en mayo 2013)
4 Pugliatti M et al. Epilepsia 2007: 48(12) 22242233.
ESTEVE APPOINTS JORDI MUNTAÑOLA AS CHIEF COMMERCIAL OFFICER FOR EUROPE
Jordi Muntañola will take on the leadership of all the pharmaceutical activities in Spain and Europeread more
POMPEU FABRA UNIVERSITY AND ESTEVE ARE TO INVESTIGATE NEW TARGETS FOR TREATING NEUROPATHIC PAIN
The RIBOPAIN project aims to identify new therapeutic solutions for pain and to develop more effective drugsread more
ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY
Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spainread more